Angiotensin receptor neprilysin inhibitor (ARNI) in right ventricular failure and preserved LV ejection fraction: A systematic review and meta-analysis

Mohsen Safari, Zeinab Safari · 2026

Read Angiotensin receptor neprilysin inhibitor (ARNI) in right ventricular failure and preserved LV ejection fraction: A systematic review and meta-analysis by Mohsen Safari, Zeinab Safari (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13688882.txt.

Description

Mohsen Safari and Zeinab Safari review a heart drug class for failure of the heart's right side, in this 2026 paper. Right ventricular failure, where the right chamber weakens while the left still pumps well, often follows lung or congenital disease. Drugs called ARNI helped left-sided failure greatly, but their value for the right side was little studied.

The pair searched five databases for trials and cohort studies through 2025. Only three studies, with 120 patients in total, qualified. The drugs improved two ultrasound measures of right chamber squeeze, lowered lung artery pressure, and cut a key stress marker in the blood. Patients walked about thirty meters farther in six minutes and felt a class better on a standard symptom scale. The authors call the signal promising while stressing how thin the evidence base is.

Catalog record

CREATORMohsen Safari, Zeinab Safari
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE15 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13688882

Browse the full library · About the Tower of Babel